Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 8—August 2023
Dispatch

Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism

Andrew B. Wolf, Kelli M. Money, Arun Chandnani, Charles L. Daley, David E. Griffith, Lakshmi Chauhan, Nathan Coffman, Amanda L. Piquet, Kenneth L. Tyler, Shanta M. Zimmer, Brian T. Montague, Sarah Mann, and Daniel M. PastulaComments to Author 
Author affiliations: University of Colorado School of Medicine, Aurora, Colorado, USA (A.B. Wolf, K.M. Money, A. Chandani, L. Chauhan, N. Coffman, A.L. Piquet, K.L. Tyler, S.M. Zimmer, B.T. Montague, S. Mann, D.M. Pastula); National Jewish Health, Denver, Colorado, USA (C.L. Daley, D.E. Griffith); Colorado School of Public Health, Aurora (D.M. Pastula)

Main Article

Table 1

Mycobacterium abscessus antibiotic susceptibilities for case-patient who underwent intrathecal stem cell injections as treatment for multiple sclerosis at a clinic in Mexico*

Antimicrobial MIC, μg/mL Interpretation
Amikacin 64 Resistant
Cefoxitin 32 Intermediate
Ciprofloxacin ≥8 Resistant
Clarithromycin 1 Susceptible
Doxycycline ≥16 Resistant
Imipenem 16 Intermediate
Linezolid 8 Susceptible
Moxifloxacin ≥8 Resistant
Tigecycline ≥8 Resistant
Trimethoprim/sulfamethoxazole ≥8/152 Resistant

*Determined by using Clinical and Laboratory Standards Institute cutpoints for resistance (7). There is no recommended cutpoint for tigecycline.

Main Article

References
  1. Johansen  MD, Herrmann  JL, Kremer  L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18:392–407. DOIPubMedGoogle Scholar
  2. Phillips  MS, von Reyn  CF. Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis. 2001;33:1363–74. DOIPubMedGoogle Scholar
  3. Wu  EL, Al-Heeti  O, Hoff  BM, et al. Role of therapeutic drug monitoring in the treatment of persistent Mycobacterium abscessus central nervous system infection: a case report and review of the literature. Open Forum Infect Dis. 2022;9:ofac392.
  4. Gaines  J, Poy  J, Musser  KA, Benowitz  I, Leung  V, Carothers  B, et al. Notes from the field: nontuberculous mycobacteria infections in US medical tourists associated with plastic surgery—Dominican Republic, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:369–70. DOIPubMedGoogle Scholar
  5. Schnabel  D, Esposito  DH, Gaines  J, Ridpath  A, Barry  MA, Feldman  KA, et al.; RGM Outbreak Investigation Team. Multistate US outbreak of rapidly growing mycobacterial infections associated with medical tourism to the Dominican Republic, 2013–20141. Emerg Infect Dis. 2016;22:1340–7. DOIPubMedGoogle Scholar
  6. Griffith  DE, Daley  CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest. 2022;161:64–75. DOIPubMedGoogle Scholar
  7. Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes, 2nd edition. CLSI standard document M24. Wayne (PA): The Institute; 2023.
  8. Nguyen  DC, Dousa  KM, Kurz  SG, Brown  ST, Drusano  G, Holland  SM, et al. “One-Two Punch”: Synergistic ß-lactam combinations for Mycobacterium abscessus and target redundancy in the inhibition of peptidoglycan synthesis enzymes. Clin Infect Dis. 2021;73:1532–6. DOIPubMedGoogle Scholar
  9. Julian  K, Yuhasz  N, Rai  W, Salerno  JA, Imitola  J. Complications from “stem cell tourism” in neurology. Ann Neurol. 2020;88:661–8. DOIPubMedGoogle Scholar
  10. Bauer  G, Elsallab  M, Abou-El-Enein  M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018;7:676–85. DOIPubMedGoogle Scholar
  11. US Centers for Disease Control and Prevention. Outbreak and patient notification: Stem cell and exosome products. 2019 Dec 19 [cited 2022 Dec 18]. https://www.cdc.gov/hai/outbreaks/stem-cell-products.html
  12. US Food and Drug Administration. Consumer update: FDA warns about stem cell therapies. 2020 Sep 9 [cited 2022 Dec 18]. https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
  13. Hartnett  KP, Powell  KM, Rankin  D, Gable  P, Kim  JJ, Spoto  S, et al. Investigation of bacterial infections among patients treated with umbilical cord blood–derived products marketed as stem cell therapies. JAMA Netw Open. 2021;4:e2128615. DOIPubMedGoogle Scholar
  14. Lee  MR, Cheng  A, Lee  YC, Yang  CY, Lai  CC, Huang  YT, et al. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother. 2012;67:222–5. DOIPubMedGoogle Scholar
  15. Novosad  SA, Beekmann  SE, Polgreen  PM, Mackey  K, Winthrop  KL; M. abscessus Study Team. M. abscessus Study Team. Treatment of Mycobacterium abscessus infection. Emerg Infect Dis. 2016;22:511–4. DOIPubMedGoogle Scholar

Main Article

Page created: June 14, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external